[PATHWAY-2 study. Vision of the family physician in the approach of resistant hypertension]
- PMID: 27422580
- DOI: 10.1016/j.hipert.2016.06.001
[PATHWAY-2 study. Vision of the family physician in the approach of resistant hypertension]
Abstract
Resistant hypertension is a relatively prevalent condition in primary care that exceeds 7% of patients with hypertension assisted in the office and that implies a high cardiovascular risk due to its association with cardiovascular events. The PATHWAY-2 study has allowed to establish that spironolactone is the best possible alternative in the fourth line of treatment for most patients. It significantly simplifies the approach of these patients for primary care physicians.
Keywords: Atención primaria; Espironolactona; Hipertensión resistente; Primary care; Resistant hypertension; Sprinolactone.
Copyright © 2016 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.
Comment on
-
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. Lancet. 2015. PMID: 26414968 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
